Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Recurrent or Metastatic Bladder Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 11 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01089088
What this trial is testing

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Cardiff University 63
Early research (Phase 1)Active Not RecruitingNCT06238479
What this trial is testing

LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Who this might be right for
Metastatic Solid TumorRecurrent Solid TumorAdvanced Solid Tumor+11 more
Eli Lilly and Company 490
Early research (Phase 1)Study completedNCT02437370
What this trial is testing

Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer

Who this might be right for
Metastatic Urothelial Carcinoma of the Renal Pelvis and UreterRecurrent Bladder CarcinomaRecurrent Urothelial Carcinoma of the Renal Pelvis and Ureter+6 more
University of California, Davis 32
Testing effectiveness (Phase 2)Looking for participantsNCT06823427
What this trial is testing

9MW2821 + Toripalimab vs 9MW2821 for 1st Line Locally Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Recurrent+1 more
Mabwell (Shanghai) Bioscience Co., Ltd. 60
Not applicableLooking for participantsNCT06349642
What this trial is testing

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

Who this might be right for
Early Stage Triple-Negative Breast CarcinomaMetastatic Bladder Urothelial CarcinomaMetastatic Cervical Carcinoma+24 more
Mayo Clinic 324
Very early researchUnknownNCT05559177
What this trial is testing

An Open, Dose-escalation Clinical Study of Chimeric Exosomal Tumor Vaccines for Recurrent or Metastatic Bladder Cancer

Who this might be right for
Recurrent or Metastatic Bladder Cancer
Shanghai Pudong Hospital 9
Testing effectiveness (Phase 2)UnknownNCT01118039
What this trial is testing

Sunitinib Malate in Treating Patients With Locally Recurrent, Locally Advanced, Unresectable, or Metastatic Urinary Tract Cancer

Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and UreterUrethral Cancer
Hospital del Mar 41
Testing effectiveness (Phase 2)WithdrawnNCT04464967
What this trial is testing

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

Who this might be right for
Advanced Solid TumorMetastatic CancerHER2-positive Breast Cancer+14 more
NKGen Biotech, Inc.
Testing effectiveness (Phase 2)Study completedNCT03602079
What this trial is testing

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Who this might be right for
HER2-positive Breast CancerHER2 Gene MutationHER-2 Gene Amplification+41 more
Klus Pharma Inc. 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT00082706
What this trial is testing

Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant

Who this might be right for
Bladder CancerUrethral CancerUrachal Cancer
M.D. Anderson Cancer Center 46
Testing effectiveness (Phase 2)Study completedNCT00112671
What this trial is testing

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract

Who this might be right for
Metastatic Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Transitional Cell Cancer of the Renal Pelvis and Ureter+4 more
National Cancer Institute (NCI) 17